Reuters logo
BRIEF-VBL Therapeutics reports full data for VB-111 monotherapy in phase 2 trial for recurrent thyroid cancer
February 21, 2017 / 12:15 PM / 10 months ago

BRIEF-VBL Therapeutics reports full data for VB-111 monotherapy in phase 2 trial for recurrent thyroid cancer

Feb 21 (Reuters) - Vascular Biogenics Ltd:

* VBL Therapeutics reports full data for vb-111 monotherapy in phase 2 trial for recurrent thyroid cancer

* Vascular Biogenics Ltd - primary endpoint of trial, defined as 6-month progression-free-survival (pfs-6) of 25 pct, was met with a dose response.

* Vascular Biogenics Ltd - an overall survival benefit was seen with a tail of more than 40 pct at 3.7 years for therapeutic-dose cohort

* Vascular Biogenics Ltd - VB-111 was well-tolerated in open-label dose-escalating study with no signs of clinically significant safety issues Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below